Matinas BioPharma Holdings, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jerome D. Jabbour
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1545 Route 206 South Bedminster NJ United States of America 07921
- IPO Date
- Jul 21, 2014
- CIK
- 0001582554
- Website
- matinasbiopharma.com
- Similar Companies
- Business
- Matinas BioPharma Holdings, Inc. (MTNB) is a clinical-stage biopharmaceutical company that develops novel therapeutics using its proprietary lipid nanocrystal (LNC) platform technology for safe, intracellular oral delivery of small molecules, small oligonucleotides, nucleic acids, gene therapies, vaccines, proteins, and peptides; its lead product candidate is MAT2203, an oral formulation of amphotericin B designed as a broad-spectrum antifungal for treating invasive fungal infections such as aspergillosis and cryptococcal meningitis in patients with limited treatment options, following successful Phase 2 EnACT trial results demonstrating primary endpoint achievement and robust survival; the company also pursues early-stage discovery programs in oncology and inflammation, including LNC-delivered oligonucleotides targeting TNFα and IL-17A for conditions like acute colitis and psoriasis. Founded in 2013 and headquartered in Bedminster, New Jersey, Matinas BioPharma operates primarily in the United States with clinical trials conducted across North America under U.S. Food and Drug Administration guidance, focusing on high-unmet-need areas in infectious diseases. Recent developments include the termination of MAT2203 partnership negotiations and implementation of workforce reductions in October 2024 to explore strategic alternatives; agreements for preferred stock acquisitions in February 2025 to fund general corporate purposes and MAT2203 advancement; appointments of seasoned biotech leaders Dr. Robin L. Smith, Evelyn D’An as Audit Committee Chair, and additional board members in early 2025; receipt of a NYSE noncompliance notice in January 2025; and demonstration of successful MAT2203 compassionate use treatment for a patient with limb-threatening mucor infection in June 2024, alongside new in vitro data on LNC oligonucleotide delivery presented at TIDES USA 2024.
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair
Matinas BioPharma Receives NYSE Noncompliance Notice
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024